People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Pharma, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intera Oncology Inc. | — | Pharma | Seed | $3.7M | $9.0M | 2019 |
| Censa Pharmaceuticals Inc. | — | Pharmaceuticals | Seed | $3.0M | $57.1M | 2016 |
| Janus Biotherapeutics, Inc. | — | Biotechnology | Seed | $2.3M | $29.0M | 2020 |
| 65Bio Inc. | — | Biotechnology | Seed | $1.8M | $77.0M | 2020 |
| Atacama Therapeutics, Inc. | — | Pharma | Pre-Seed | $830K | $4.2M | 2024 |
Jonathan Reis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Reis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joseph Baron | 5 | 5 |
| David Dove | 2 | 2 |
| PINI ORBACH | 1 | 2 |
| Christine De Los Reyes | 1 | 2 |
| Chris Schelling | 1 | 2 |
| Grayson Lipford | 1 | 1 |
| Michael Gaisford | 1 | 1 |
| Josh Goldberg | 1 | 1 |
| Daniel Gressel | 1 | 1 |
| Steven Bernitz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.